1. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma
    XIA YING et al, 2014 CrossRef
  2. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin
    HAIPENG ZHU et al, 2015 CrossRef
  3. IGFBP, a novel target of lung cancer?
    Qiongge Hu et al, 2017, Clinica Chimica Acta CrossRef
  4. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer
    Pei Li et al, 2017, Tumour Biol. CrossRef
  5. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer
    Peng Wang et al, 2018, J Cell Biochem CrossRef
  6. null
    Giulio Tarro et al, 2019 CrossRef
  7. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma.
    Li-Ling Luo et al, 2015, Sci Rep CrossRef
  8. Determination of IGFs and their binding proteins
    Rikke Hjortebjerg et al, 2013, Best Practice & Research Clinical Endocrinology & Metabolism CrossRef
  9. Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival
    Chengcheng Guo et al, 2013, PLoS ONE CrossRef
  10. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Zachary W Kendrick et al, 0 CrossRef
  11. Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review
    Bin Yang et al, 2019, Cell Death Discov. CrossRef
  12. Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
    Jing Jia et al, 2014, PLoS ONE CrossRef
  13. null
    Nicola Bizzaro et al, 2014 CrossRef
  14. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer
    Chun-Hua Xu et al, 2014, Tumor Biol. CrossRef
  15. IGFBP-2 - taking the lead in growth, metabolism and cancer
    Steven W. Yau et al, 2015, J. Cell Commun. Signal. CrossRef
  16. null
    Hoseok I et al, 2015 CrossRef
  17. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response
    Christina Pfirschke et al, 2015, Cancer Immunol Immunother CrossRef
  18. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer
    Xiaofeng Yao et al, 2016, Tumor Biol. CrossRef
  19. Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer
    Jie Dong et al, 2019, Nutrition and Cancer CrossRef
  20. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis
    Zhen-Ming Tang et al, 2017, PLoS ONE CrossRef
  21. Establishment and validation of an immunodiagnostic model for prediction of breast cancer
    Cuipeng Qiu et al, 2019, OncoImmunology CrossRef
  22. IGFBP2: integrative hub of developmental and oncogenic signaling network
    Tao Li et al, 2020, Oncogene CrossRef
  23. Prognostic Value of Circulating IGFBP2 and Related Autoantibodies in Children with Metastatic Rhabdomyosarcomas
    Elena Poli et al, 2020, Diagnostics CrossRef
  24. null
    Xiuzhi Zhang et al, 2020 CrossRef
  25. Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma
    Chih-Ching Wu et al, 2014, Cancer Epidemiol Biomarkers Prev CrossRef
  26. Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses.
    Denise L Cecil et al, 2021, Clin Cancer Res CrossRef
  27. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer
    Alexander W. Pohlman et al, 2022, Oncotarget CrossRef
  28. Blood protein biomarkers in lung cancer
    Hong Huang et al, 2022, Cancer Letters CrossRef